Workflow
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
ADMAADMA Biologics(ADMA) GlobeNewswire·2025-05-08 04:05

1Q 2025 Total Revenue of 114.8Million(AdjustedTotalRevenueof114.8 Million (Adjusted Total Revenue of 118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of 26.9Million,a5126.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA of 47.9 Million, an 81% YoY Increase 1Q 2025 Adjusted Net Income of 33.3Million,an8733.3 Million, an 87% YoY Increase 1Q 2025 Total Cash and Receivables Grew to Approximately 171 Million FDA Approved Yield Enhancement Process Anticipated to Provide 20% Production Output Enhancement from Same Starting Plasma Volume, and Support Revenue ...